A Phase 3 Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of
treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The
primary objective of this study is to assess the efficacy of two dose levels of brepocitinib
in comparison to placebo, as measured by differences in the Total Improvement Score (TIS).